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Meeting Highlight
3rd Biannual Meeting: “Trends in Invasive Fungal Infection»
T h e  b i a n n u a l  meeting “Trends in Invasive Fungal Infections 
3” was held in Brussels from 7 to 9 September 1995, During the 
meetings many presentations were made on the management of 
fungal infections in cancer patients. Of some concern, were 
reports that indicated an increasing incidence of unusual fungal 
pathogens in cancer patients; for instance, a recent survey by 
the EORTC’s Invasive Fungal Infection Cooperative Group 
identified such strains in 22 out of 270 cases with fungaemia. It 
has been commonly believed that fungaemia caused by yeasts 
and invasive candidiasis were almost exclusively the result of 
endogenous proliferation and invasion in patients without cen­
tral venous catheters, but increasing evidence points at the 
possibility of exogenous sources, such as the hands of health care 
professionals. Another striking observation was the increase of 
breakthrough fungaemias in patients already receiving empiric 
antifungal therapy.
John Rex provided details of a major randomised study which 
compared conventional amphotericin B with fluconazole in 
patients with candidaemia. Ocular lesions consistent with 
endophthalmitis were encountered in 15% of patients, which 
was considered to be strong evidence for routine fundoscopy in 
patients with, or suspected of, a fungaemia. The final results of 
this therapeutic trial showed that fluconazole offers a safe 
alternative to amphotericin B, at least in fungaemias caused by 
Candida albicans in non-neutropenic patients. Yet, removal of a 
catheter, whenever possible, appeared to be a key issue for a 
favourable outcome.
The association between risk factors and outcome were also 
stressed by John Edwards, reporting on the unexpectedly high 
incidence of yeast infections caused by non-Candida species. 
The risk factors may be institutionally dependent, particularly 
in some epidemiological circumstances. Moreover, he demon­
strated a relationship between carriage of yeasts on the hands of 
health workers and common isolates in a given institute or unit 
by means of DNA typing of pathogenic strains. Indeed^ 35-75% 
of nurses were shown to carry Candida species on their hands. 
However, the risk of invasive candidiasis is often unpredictable 
in cancer patients since approximately 50% of cases with can­
didaemia had negative surveillance cultures.
His data on the increasing incidence of non-albicans candidae­
mia and institutional clustering were corroborated by Claudio 
Viscoli who was the co-ordinator of the first large European 
survey on 270 cases of fungaemia in cancer patients. This study 
was conducted under auspices of the EORTC’s Invasive Fungal 
Infection Cooperative Group in cancer patients from 30 centres 
throughout Europe. A registered mortality rate of 40% within 1 
month following the positive blood culture for yeasts was 
comparable to that reported by major centres in the U.S.A.
Breakthrough fungaemia during chemoprophylaxis or empiric 
antifungal therapy was a commonly observed clinical entity, 
Candida tropicalis fungaemia carried the highest mortality which 
amounted to 60%. Another dismal parameter was the presence 
of shock which, under normal circumstances, is rarely primarily 
associated with candidaemia in the differential diagnosis of 
such cases. Considering the likelihood of candidaemia remains, 
therefore, of paramount importance in obtaining a proper diag­
nosis in patients who are treated intensively for a haematological 
malignancy or solid tumour.
Robert De Bock called attention to the ongoing study of the 
EORTC’s Invasive Fungal Infection Cooperative Group which 
compares fluconazole with itraconazole for oropharyngeal can­
didiasis in cancer patients. This trial represents the first direct 
comparison of these triazoles in order to establish their respective 
roles in the treatment of a condition which may precede dissemi­
nated candidiasis, especially in immunocompromised patients.
In the field of prevention and chemoprophylaxis of fungal 
infections in neutropenic patients with cancer, personal and 
environmental hygiene is still the mainstay, as there is no 
consensus with regard to optimal agent or recommended dose. 
A wide dose range, varying from 50 to 400 mg per day, of 
fluconazole has been used in a prophylactic setting but no clear 
dose-effect relationship could be ascertained for this drug that 
constitutes the most extensively tested compound in this area. 
Since fluconazole offers no protection against aspergillosis, 
centres with a high incidence of these infections have to consider 
other options. However, neither the data on the prophylactic 
use of amphotericin B, either orally or by aerosol or at a low dose 
intravenously, nor those on itraconazole (with the currently 
available preparation) or nystatin, are encouraging. For insti­
tutions with an excess of invasive candidiasis, fluconazole could 
be, at least in part, a solution to the problem, particularly in 
individuals with a substantial amount of Candida albicans in 
their surveillance cultures. On the basis of the data available 
from randomised studies, a dose of 200 mg per day seems to be 
acceptable in Europe.
Marc Boogaerts described the indications and strategy for 
empiric antifungal therapy. As yet, the most appropriate time to 
initiate empiric treatment with systematically active antifungal 
agents remains obscure, partly due to the lack of adequate data 
on this subject, and partly because the majority of persistently 
febrile neutropenic patients do not suffer from an occult fungal 
infection. Hence, when such an intervention is deliberated, the 
balance betwen the risks and possible benefits of systemic 
antifungal therapy should be considered. More careful studies 
are required to define which group of patients would benefit 
from an empiric approach and to appraise the optimal time to
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begin the antifungal drugs. Treatment of a documented fungal 
infection constitutes a major challenge, especially where there is 
concomitant granulocytopenia, where the outcome is dismal that 
all reservations concerning intrinsic adverse effects of empiric 
administration of antifungal drugs are irrelevant until more 
effective therapy has been developed or until the risk groups 
have been better defined.
Koen Torfs presented information on economical aspects of 
the treatment of fungal infection in cancer patients and described 
the tools to assess the related costs, including widespread use of 
expensive formulations of Ambisome or growth factors.
Fritz Offner reviewed the indications for and influence of 
haematopoietic growth factors in invasive fungal infections. 
Once again, the need for more data on their efficacy in patients 
with a documented fungal infection was apparent. The results 
from the clinical situation are somewhat confusing since* before 
the fungal infection emerged, most patients already had been 
treated with a growth factor for other purposes. A careful 
cost-benefit analysis by means of prospectively randomised 
clinical trials, with a stratification for documented fungal infec­
tions is mandatory in patients with prolonged and profound 
neutropenia. Such an investigation should include an assessment 
of the impact of the employment of growth factors on long-term 
survival. So far, no significantly improved survival has been 
reported, indicating that there is a need for better definition of 
patients with a proven or presumed fungal infection who might 
benefit from the administration of growth facotrs. None of the 
studies hitherto have established a role for the haematopoietic 
growth factors in a prophylatic setting and it seems obvious that 
they cannot substitute for phagocytic cells. Finally, it was 
mentioned that there are still concerns about unrestricted use 
of haematopoietic growth factors in patients with acute non- 
lymphoblastic leukaemia.
Elias Anaissie, however, found an original way to use haemato­
poietic growth factors to improve the prognosis of patients with 
a therapy-refractory documented invasive fungal infection. He 
pretreated healthy donors with growth factors and, not surpris­
ingly, the harvest by leucopheresis yielded unequaled high 
numbers of white cells that could be given successfully to 
patients.
Overall, the aim of this international meeting was to provide a 
platform for scientific exchange, to supply up-to-date infor­
mation and to stimulate informal discussions between interested 
colleagues. This goal was accomplished by a multidisciplinary 
approach of epidemiology, diagnostic tools, and actual clinical
issues, including new antifungal agents and innovative thera­
peutic strategies. All these items were discussed by leaders in 
the field and it became clear that, although substantial progress 
has been made during the last decade, we are left with more 
questions than answers. Several controversial issues regarding 
diagnostic procedures, supportive measures, and therapeutic 
and prophylactic interventions urgently need to be addressed by 
clinical investigators in close co-operation with microbiologists 
and mycologists involved in the care of patients at risk of, or 
suffering from, fungal infections.
A follow-up meeting, of which the location remains to be 
determined, has been planned for 1997, where hopefully some 
answers to the most vital questions of today will be given. For 
this purpose, clinical trials with an adequate number of patients 
and proper definitions of risk factors have to be designed and 
conducted. Multicentre co-operation, providing independent 
and objective evaluation, is essential to allow sufficient recruit­
ment, and to avoid results that have too low a statistical power 
to produce generally applicable guidelines for the treatment of 
patients with fungal infections. If this cannot be accomplished, 
doctors will have to continue to rely upon data that are at best 
suggestive, or on assumptions, or intuition.
Facing the challenge of fungal infections in neutropenic cancer 
patients, a new EORTC cooperative group was created in 1991. 
The aims of this Invasive Fungal Infections Cooperative Group 
are: (i) to conduct, develop, coordinate and stimulate research 
on the epidemiology, diagnosis, prevention and treatment of 
invasive fungal infections which constitute a real life-threatening 
infectious complication in patients who are treated for a malig­
nancy; (ii) to increase the awareness of physicians, nurses and all 
other health care workers with regard to the morbidity and 
mortality associated with invasive fungal infections; (iii) to 
provide insight in the economical burden originating from fungal 
infections to the society and health care systems.
Such international cooperation is required to guarantee a high 
quality of clinical research in this difficult field of assessing 
optimal strategies. Any information on clinical research or 
ongoing activities of the EORTC’s Invasive Fungal Infections 
Cooperative Group can be obtained from Ann Marinus, data 
manager of the group at the EORTC Data Centre (83, Ave E. 
Mounier, B-I200 Brussels, Belgium, Tel.: +32-2-774 16 54; 
Fax: +32-2-772 35 43.)
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